| Theme | Treatment Strategy for Advanced Hepatocellular Carcinoma | |
|---|---|---|
| Title | Significance of the Molecular Target Medicine as Adjuvant Chemotherapy after Curative Treatment | |
| Publish Date | 2015/07 | |
| Author | Takahiro Kajiwara | Devision of Digestive Surgery, Nihon University School of Medicine |
| Author | Masamichi Moriguchi | Devision of Digestive Surgery, Nihon University School of Medicine |
| Author | Tadatoshi Takayama | Devision of Digestive Surgery, Nihon University School of Medicine |
| [ Summary ] | Sorafenib is a multikinase inhibitor with proven efficacy in unresectable HCC. The STORM trial was a phase III randomized, double‒blind, placebo‒controlled trial of adjuvant sorafenib after resection or ablation to prevent recurrence of HCC. This study evaluated the efficacy and safety of adjuvant sorafenib for HCC. No differences between groups in recurrence‒free survival (RFS), time to recurrence (TTR) and overall survival (OS) were observed. The adverse events were consistent with the known sorafenib safety profile and no new safety findings were observed. Development of additional molecularly targeted drugs with an antitumor effect is necessary, and examination of these targeted treatments in conjunction with IFN or peretinoin is also necessary. |
|